Search Results - "PANZARA, M"

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function by KHARRI, B. O, MAN, S, DUDA, P. W, PANZARA, M. A, RANSOHOFF, R. M, FOX, R. J, GIOVANNONI, G, KOO, A. P, LEE, J.-C, TUCKY, B, LYNN, F, JURGENSEN, S, WOODWORTH, J, GOELZ, S

“…Accelerating the clearance of therapeutic monoclonal antibodies (mAbs) from the body may be useful to address uncommon but serious complications from…”
Get full text

Clinical pharmacology of alemtuzumab, an anti‐CD52 immunomodulator, in multiple sclerosis by Li, Z., Richards, S., Surks, H. K., Jacobs, A., Panzara, M. A.

“…Summary Alemtuzumab, a humanized anti‐CD52 monoclonal antibody, is approved for treatment of relapsing multiple sclerosis (MS). In the Phase II/III trials,…”
Get full text

Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire by Benedict, RHB, Duquin, JA, Jurgensen, S, Rudick, RA, Feitcher, J, Munschauer, FE, Panzara, MA, Weinstock-Guttman, B

“…Background Brief cognitive performance tests and self-report measures of neuropsychological symptoms have been proposed for screening purposes in multiple…”
Get full text

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS by MILLER, D. H, SOON, D, KAPPOS, L, HUTCHINSON, M, HAVRDOVA, E, LUBLIN, F. D, GIOVANNONI, G, WAJGT, A, RUDICK, R, LYNN, F, PANZARA, M. A, SANDROCK, A. W, FERNANDO, K. T, MACMANUS, D. G, BARKER, G. J, YOUSRY, T. A, FISHER, E, O'CONNOR, P. W, PHILLIPS, J. T, POLMAN, C. H

“…In a 2-year, placebo-controlled trial (the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis [AFFIRM] study), involving 942 patients…”
Get full text

GLANCE : Results of a phase 2, randomized, double-blind, placebo-controlled study by GOODMAN, A. D, ROSSMAN, H, PANZARA, M. A, SANDROCK, A. W, BAR-OR, A, MILLER, A, MILLER, D. H, SCHMIERER, K, LUBLIN, F, KHAN, O, BORMANN, N. M, YANG, M

“…To evaluate the safety and tolerability of natalizumab when added to glatiramer acetate (GA) in patients with relapsing multiple sclerosis. The primary outcome…”
Get full text

Progressive MS Alliance Industry Forum: Maximizing Collective Impact To Enable Drug Development by Zaratin, P, Comi, G, Coetzee, T, Ramsey, K, Smith, K, Thompson, A, Panzara, M

“…The Progressive MS Alliance Industry Forum describes a new approach to address barriers to developing treatments for progressive multiple sclerosis (MS). This…”
Get full text

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL by Hutchinson, M., Kappos, L., Calabresi, P. A., Confavreux, C., Giovannoni, G., Galetta, S. L., Havrdova, E., Lublin, F. D., Miller, D. H., O’Connor, P. W., Phillips, J. T., Polman, C. H., Radue, E.-W., Rudick, R. A., Stuart, W. H., Wajgt, A., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A.

“…The AFFIRM and SENTINEL studies showed that natalizumab was effective both as monotherapy and in combination with interferon beta (IFNβ)-1a in patients with…”
Get full text

Assessing disability progression with the Multiple Sclerosis Functional Composite by Rudick, RA, Polman, CH, Cohen, JA, Walton, MK, Miller, AE, Confavreux, C, Lublin, FD, Hutchinson, M, O’Connor, PW, Schwid, SR, Balcer, LJ, Lynn, F, Panzara, MA, Sandrock, AW

“…Background The initial Multiple Sclerosis Functional Composite (MSFC) proposal was a three-part composite of quantitative measures of ambulation, upper…”
Get full text

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis by BALCER, L. J, GALETTA, S. L, O'CONNOR, P. W, PHILLIPS, J. T, POLMAN, C. H, RADUE, E.-W, RUDICK, R. A, STUART, W. H, WAJGT, A, WEINSTOCK-GUTTMAN, B, WYNN, D. R, LYNN, F, CALABRESI, P. A, PANZARA, M. A, CONFAVREUX, C, GIOVANNONI, G, HAVRDOVA, E, HUTCHINSON, M, KAPPOS, L, LUBLIN, F. D, MILLER, D. H

“…To examine the effects of natalizumab on low-contrast letter acuity as a prespecified tertiary endpoint in two randomized clinical trials and to evaluate the…”
Get full text

Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a by RUDICK, R. A, PACE, A, GALETTA, S. L, LUBLIN, F. D, RADUE, E.-W, RANSOHOFF, R. M, RANI, M. R. S, HYDE, R, PANZARA, M, APPACHI, S, SHROCK, J, MAURER, S. L, CALABRESI, P. A, CONFAVREUX, C

“…Findings from a small clinical study suggested that statins may counteract the therapeutic effects of interferon beta (IFNbeta) in patients with…”
Get full text

Infusion-related hypersensitivity reactions during natalizumab treatment by PHILLIPS, J. T, O'CONNOR, P. W, LYNN, F, PANZARA, M. A, SANDROCK, A. W, HAVRDOVA, E, HUTCHINSON, M, KAPPOS, L, MILLER, D. H, POLMAN, C. H, LUBLIN, F. D, GIOVANNONI, G, WAJGT, A

Get full text

Alemtuzumab improves visual outcomes in treatment-naïve patients with relapsing–/INS;remitting multiple sclerosis (RRMS): Analysis from the phase 3 CARE-MS I study by Balcer, L.J, Arnold, D.L, Cohen, J.A, Coles, A.J, Confavreux, C, Fox, E.J, Hartung, H.-P, Havrdova, E, Selmaj, K.W, Weiner, H.L, Brinar, V, Giovannoni, G, Stojanovic, M, Cinar, A, Margolin, D.H, Panzara, M, Compston, D.A.S

Get full text

Adverse event profile of alemtuzumab over time in treatment-naïve patients with early, active relapsing–/INS;remitting multiple sclerosis (RRMS; CARE-MS I study) by Lycke, J, Arnold, D.L, Cohen, J.A, Coles, A.J, Confavreux, C, Fox, E.J, Hartung, H.-P, Havrdova, E, Selmaj, K.W, Weiner, H.L, Brinar, V, Giovannoni, G, Stojanovic, M, Lake, S.L, Margolin, D.H, Panzara, M, Compston, D.A.S

Get full text

Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A CARE-MS substudy by Margolin, D.H, Rizzo, M.A, Smith, G, Arnold, D.L, Cohen, J.A, Coles, A.J, Confavreux, C, Fox, E.J, Hartung, H.-P, Havrdova, E, Selmaj, K.W, Weiner, H.L, Brinar, V, Giovannoni, G, Miller, T.A, Stojanovic, M, Twyman, C.L, Lake, S.L, Panzara, M, Compston, D.A.S

Get full text

Selection for T-cell receptor Vβ-Dβ-Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis by Oksenberg, Jorge R, Panzara, Michael A, Begovich, Ann B, Mitchell, Dennis, Erlich, Henry A, Murray, Ronald S, Shimonkevitz, Richard, Sherritt, Martina, Rothbard, Jonathan, Bernard, Claude C. A, Steinman, Lawrence

“…Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system in which a restricted cellular immune response has been…”
Get full text

Analysis of the T cell repertoire using the PCR and specific oligonucleotide primers by Panzara, M A, Gussoni, E, Steinman, L, Oksenberg, J R

“…Applications of PCR have revolutionized the field of immunogenetics particularly in studies of human leukocyte antigen class II polymorphism and more recently…”
Get more information

P22 WVE-N531 yields 53% mean exon 53 skipping in skeletal muscle of boys with Duchenne muscular dystrophy (DMD) after three biweekly doses by Tillinger, M., Lake, S., Servais, L., Campbell, C., Xu, X., Hart, A., Haegele, J., Singh, K., Rheinhardt, J., Ghosh, A., Xu, D., Panzara, M., Li-Kwai-Cheung, A.

“…WVE-N531 is an investigational stereopure antisense oligonucleotide being developed as a potential therapy for patients with DMD amenable to exon 53 skipping…”
Get full text

FP.12 Application for primary endpoint qualification of the 95th centile of stride velocity (SV95C) in Duchenne muscular dystrophy by Annoussamy, M., Eggenspieler, D., Seferian, A., Mercuri, E., Straub, V., Muntoni, F., Scoto, M., Poleur, M., Daron, A., Butoianu, N., Mirea, A., Goemans, N., Previtali, S., Tulinius, M., Nascimento, A., Heydemann, P., Panzara, M., Singh, T., Strijbos, P., Servais, L.

Get full text

O.28Safety and tolerability of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy: results from a phase 1 clinical trial by Wagner, K., Phan, H., Servais, L., Gidaro, T., Cripe, L., Eagle, M., Muntoni, F., Straub, V., Lonkar, P., Schmitz, S., Lake, S., Hu, X., Panzara, M.

Get full text

EP.83Design of a Phase 2/3 randomized controlled trial of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy amenable to exon 51 skipping by Wagner, K., Cripe, L., Eagle, M., Muntoni, F., Niks, E., Phan, H., Straub, V., Hu, X., Antonijevic, I., Berry, S., Quintana, M., Lake, S., Panzara, M.

Get full text